Papillomavirus Vaccines Clinical Trial
Official title:
Understanding and Addressing the Disparity in Vaccination Coverage Among U.S. Adolescents Living in Rural Versus Urban Areas
Vaccine uptake in the United States is lower in rural areas, especially for HPV vaccine. Reminder/recall has been identified as an effective strategy to increase vaccination rates. This study will assess the impact by rurality of vaccine reminder notices sent via the parent's preferred method of communication on HPV vaccination among 12 year-old patients in a regional healthcare system.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00359619 -
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
|
Phase 2 | |
Completed |
NCT00250276 -
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
|
Phase 3 | |
Completed |
NCT01031069 -
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
|
Phase 4 | |
Recruiting |
NCT05266898 -
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
|
Phase 4 | |
Completed |
NCT03763565 -
Effectiveness of HPV Vaccine in Thai Adult Women
|
||
Completed |
NCT00877877 -
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
|
Phase 3 | |
Completed |
NCT00811798 -
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
|
Phase 3 | |
Recruiting |
NCT05884697 -
Let's K-Talk - HPV Study for Ethnic Koreans
|
N/A | |
Completed |
NCT00637195 -
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
|
Phase 3 | |
Completed |
NCT00798265 -
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
|
Phase 1 | |
Completed |
NCT00423046 -
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
|
Phase 3 | |
Completed |
NCT00294047 -
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
|
Phase 3 | |
Recruiting |
NCT04469569 -
Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
|
N/A | |
Not yet recruiting |
NCT04671823 -
Changes in the Prevalence of Oncogenic HPV Types
|
||
Recruiting |
NCT03350698 -
Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination
|
Phase 4 | |
Completed |
NCT02370459 -
AFIX to Improve HPV Vaccination
|
N/A | |
Completed |
NCT00456807 -
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
|
Phase 3 | |
Completed |
NCT03501992 -
Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination
|
N/A |